AR054857A1 - Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR054857A1 AR054857A1 ARP060103167A ARP060103167A AR054857A1 AR 054857 A1 AR054857 A1 AR 054857A1 AR P060103167 A ARP060103167 A AR P060103167A AR P060103167 A ARP060103167 A AR P060103167A AR 054857 A1 AR054857 A1 AR 054857A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- cycloalkyl
- alkylene
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procedimiento de preparacion y aplicacion en terapéutica. Reivindicacion 1: Un compuesto que responde a la formula (1), en la que: X1, X2, X3, X4 representan, independientemente uno de otro, un átomo de hidrogeno o de halogeno o un grupo alquilo C1- 6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, ciano, C(O)NR1R2, nitro, NR1R2, tioalquilo C1-6, -S(O)-alquiloC1-6, -S(O)2-alquiloC1-6, SO2NR1R2, NR3COR4, NR3SO2R5 o arilo, estando el arilo opcionalmente sustituido con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; W representa un grupo bicíclico fusionado de la formula (2), unido al átomo de nitrogeno por las posiciones 1, 2, 3 o 4; A representa un heterociclo de 5 a 7 eslabones que comprende de uno a tres heteroátomos elegidos entre O, S o N; estando el o los átomos de carbono de A opcionalmente sustituidos con uno o varios grupos elegidos entre un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, arilo, aril-alquilenoC1-6, oxo o tio; estando el o los átomos de nitrogeno de A opcionalmente sustituidos con R6 cuando el nitrogeno es adyacentes a un átomo de carbono sustituido con un grupo oxo, o con R7 en los otros casos; n es igual a 1, 2 o 3; Y representa un heteroarilo opcionalmente sustituido con uno o varios grupos elegidos entre un átomo de halogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, hidroxilo, alcoxilo C1-6, fluoroalcoxilo C1-6, ciano, C(O)NR1R2, tioalquilo C1-6, SH, -S(O)- alquiloC1-6, -S(O)2-alquiloC1-6, SO2NR1R2, NR3COR4, NR3SO2R5, aril-alquilenoC1-6 o arilo, estando el arilo y el aril-alquilenoC1-6 opcionalmente sustituidos con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R1 y R2, representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil3-7-alquilenoC1-3, aril-alquilenoC1-6 o arilo; o R1 y R2 forman conjuntamente, con el átomo de nitrogeno que les lleva, un grupo azetidinilo, pirrolidinilo, piperidinilo, azepinilo, morfolinilo, tiomorfolinilo, piperazinilo, homopiperazinilo, estando este grupo opcionalmente sustituido con un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3-, aril-alquileno C1-6 o arilo; R3 y R4 representan, independientemente uno de otro, un átomo de hidrogeno o un grupo alquilo C1-6, aril-alquilenoC1-6 o arilo; R5 representa un grupo alquilo C1-6, aril-alquilenoC1-6 o arilo; R6 representa un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, aril- alquilenoC1-6 o arilo; R7 representa un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquilenoC1-3, fluoroalquilo C1-6, aril-alquilenoC1-6, alquilC1-6-C(O)-, cicloalquilC3-7-alquilenC1-3-(CO)-, fluoroalquilC1-6-C(O)- , cicloalquilC3-7-C(O)-, aril-C(O)-, aril-alquilenC1-6-C(O)-, alquilC1-6-S(O)2-, fluoroalquilC1-6-S(O)2-, cicloalquilC3-7-S(O)2-, cicloalquilC3-7-alquilenC1-3-S(O)2-, aril-S(O)2-, o aril-alquilenC1-6-S(O)2- o arilo; pudiendo estar el o los átomos de azufre del heterociclo A o del heterociclo Y en forma oxidada; pudiendo estar el o los átomos de nitrogeno del heterociclo A o del heteroarilo Y en forma oxidada; en el estado de base o de sal de adicion de ácido, así como en el estado de hidrato o de solvato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0507803A FR2888847B1 (fr) | 2005-07-22 | 2005-07-22 | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054857A1 true AR054857A1 (es) | 2007-07-18 |
Family
ID=36156910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103167A AR054857A1 (es) | 2005-07-22 | 2006-07-21 | Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US7745467B2 (es) |
| EP (1) | EP1910335B1 (es) |
| JP (1) | JP5281890B2 (es) |
| KR (1) | KR20080027864A (es) |
| CN (1) | CN101228152B (es) |
| AR (1) | AR054857A1 (es) |
| AU (1) | AU2006271524B2 (es) |
| BR (1) | BRPI0613758A2 (es) |
| CA (1) | CA2615751C (es) |
| CR (1) | CR9590A (es) |
| EA (1) | EA013748B1 (es) |
| EC (1) | ECSP088084A (es) |
| FR (1) | FR2888847B1 (es) |
| HK (1) | HK1123050A1 (es) |
| IL (1) | IL188643A (es) |
| MA (1) | MA29698B1 (es) |
| MX (1) | MX2008001019A (es) |
| MY (1) | MY146545A (es) |
| NI (1) | NI200800015A (es) |
| NO (1) | NO20080871L (es) |
| NZ (1) | NZ565148A (es) |
| TN (1) | TNSN07469A1 (es) |
| TW (1) | TWI386402B (es) |
| UA (1) | UA93687C2 (es) |
| UY (1) | UY29690A1 (es) |
| WO (1) | WO2007010144A1 (es) |
| ZA (1) | ZA200800438B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| WO2008042571A2 (en) * | 2006-09-29 | 2008-04-10 | Smithkline Beecham Corporation | Substituted indole compounds |
| FR2911605B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique |
| FR2911604B1 (fr) | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2919610B1 (fr) * | 2007-08-02 | 2009-10-16 | Sanofi Aventis Sa | Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique |
| BRPI0812594A2 (pt) * | 2007-08-10 | 2015-06-23 | Lundbeck & Co As H | Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo. |
| FR2926555B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| US8309581B2 (en) * | 2009-09-29 | 2012-11-13 | Hoffmann-La Roche Inc. | Benzimidazole derivatives |
| JP6331882B2 (ja) * | 2014-08-28 | 2018-05-30 | ソニー株式会社 | 送信装置、送信方法、受信装置および受信方法 |
| CN112996529A (zh) * | 2018-10-02 | 2021-06-18 | 迪斯克医药公司 | Matriptase 2抑制剂及其用途 |
| WO2024026290A1 (en) * | 2022-07-25 | 2024-02-01 | Cayman Chemical Company Incorporated | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| DE10147672A1 (de) | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| DE60325025D1 (de) * | 2002-02-15 | 2009-01-15 | Glaxo Group Ltd | Modulatoren des vanilloidrezeptors |
| WO2004056768A2 (en) | 2002-12-20 | 2004-07-08 | Bayer Healthcare Ag | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
| US7531558B2 (en) * | 2003-02-14 | 2009-05-12 | Glaxo Group Limited | Carboxamide derivatives |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2888848B1 (fr) | 2005-07-22 | 2007-09-28 | Sanofi Aventis Sa | Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
-
2005
- 2005-07-22 FR FR0507803A patent/FR2888847B1/fr active Active
-
2006
- 2006-07-20 ZA ZA200800438A patent/ZA200800438B/xx unknown
- 2006-07-20 MX MX2008001019A patent/MX2008001019A/es active IP Right Grant
- 2006-07-20 WO PCT/FR2006/001782 patent/WO2007010144A1/fr active Application Filing
- 2006-07-20 UA UAA200802260A patent/UA93687C2/ru unknown
- 2006-07-20 NZ NZ565148A patent/NZ565148A/en not_active IP Right Cessation
- 2006-07-20 JP JP2008522023A patent/JP5281890B2/ja not_active Expired - Fee Related
- 2006-07-20 AU AU2006271524A patent/AU2006271524B2/en not_active Ceased
- 2006-07-20 EP EP06778898.4A patent/EP1910335B1/fr active Active
- 2006-07-20 BR BRPI0613758-0A patent/BRPI0613758A2/pt not_active Application Discontinuation
- 2006-07-20 MY MYPI20063488A patent/MY146545A/en unknown
- 2006-07-20 EA EA200800403A patent/EA013748B1/ru not_active IP Right Cessation
- 2006-07-20 CA CA2615751A patent/CA2615751C/fr not_active Expired - Fee Related
- 2006-07-20 KR KR1020087001596A patent/KR20080027864A/ko not_active Application Discontinuation
- 2006-07-20 CN CN2006800266935A patent/CN101228152B/zh not_active Expired - Fee Related
- 2006-07-21 TW TW095126729A patent/TWI386402B/zh not_active IP Right Cessation
- 2006-07-21 AR ARP060103167A patent/AR054857A1/es unknown
- 2006-07-21 UY UY29690A patent/UY29690A1/es unknown
-
2007
- 2007-12-12 TN TNP2007000469A patent/TNSN07469A1/en unknown
- 2007-12-13 CR CR9590A patent/CR9590A/es not_active Application Discontinuation
-
2008
- 2008-01-07 IL IL188643A patent/IL188643A/en not_active IP Right Cessation
- 2008-01-08 US US11/970,878 patent/US7745467B2/en not_active Expired - Fee Related
- 2008-01-09 EC EC2008008084A patent/ECSP088084A/es unknown
- 2008-01-17 NI NI200800015A patent/NI200800015A/es unknown
- 2008-02-12 MA MA30646A patent/MA29698B1/fr unknown
- 2008-02-19 NO NO20080871A patent/NO20080871L/no not_active Application Discontinuation
-
2009
- 2009-01-13 HK HK09100335.5A patent/HK1123050A1/xx not_active IP Right Cessation
-
2010
- 2010-05-11 US US12/777,846 patent/US8318775B2/en not_active Expired - Fee Related
-
2012
- 2012-10-23 US US13/658,412 patent/US8735432B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054857A1 (es) | Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR064937A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR057668A1 (es) | Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparacion, composiciones farmaceuticas y su aplicacion en terapeutica | |
| AR062143A1 (es) | Derivados de n-(amino- heteroaril)-1h-indol-2-carboxamidas y un procedimiento de preparacion | |
| AR070207A1 (es) | Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica | |
| ES2297727T3 (es) | Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos. | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| CO5721001A2 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
| NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| CO5690582A2 (es) | Derivados de n-tiazol-2-il-benzamida | |
| CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos | |
| EA200971061A1 (ru) | Пиримидоновые соединения гетероариламидов | |
| NI200600279A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| AR052450A1 (es) | Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |